OTCMKTS:ENZN - Enzon Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2665 +0.01 (+3.90 %)
(As of 06/20/2018 02:58 PM ET)
Previous Close$0.2611
Today's Range$0.2610 - $0.27
52-Week Range$0.03 - $0.40
Volume1,800 shs
Average Volume19,548 shs
Market Capitalization$11.54 million
P/E Ratio2.90
Dividend YieldN/A
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio16.00
Quick Ratio16.00


Trailing P/E Ratio2.90
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.38 million
Price / Sales1.41
Cash Flow$0.1257 per share
Price / Cash2.12
Book Value$0.21 per share
Price / Book1.27


EPS (Most Recent Fiscal Year)N/A
Net Income$5.44 million
Net Margins64.54%
Return on Equity42.94%
Return on Assets41.27%


Outstanding Shares44,220,000

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How often does Enzon Pharmaceuticals pay dividends? What is the dividend yield for Enzon Pharmaceuticals?

Enzon Pharmaceuticals announced a dividend on Tuesday, August 15th. Stockholders of record on Wednesday, August 30th will be paid a dividend of $0.15 per share on Thursday, September 28th. The ex-dividend date is Friday, September 29th. View Enzon Pharmaceuticals' Dividend History.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) posted its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.01) EPS for the quarter. The biotechnology company earned $0.02 million during the quarter. Enzon Pharmaceuticals had a net margin of 64.54% and a return on equity of 42.94%. View Enzon Pharmaceuticals' Earnings History.

When is Enzon Pharmaceuticals' next earnings date?

Enzon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Enzon Pharmaceuticals.

Who are some of Enzon Pharmaceuticals' key competitors?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the folowing people:
  • Mr. Andrew Rackear J.D., CEO & Sec. (Age 64)
  • Mr. Richard L. Feinstein CPA, VP of Fin. & CFO (Age 75)

Has Enzon Pharmaceuticals been receiving favorable news coverage?

News stories about ENZN stock have trended somewhat positive this week, according to Accern. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzon Pharmaceuticals earned a daily sentiment score of 0.08 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 44.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Enzon Pharmaceuticals' major shareholders?

Enzon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include COUCHMAN JONATHAN (10.60%) and COUCHMAN PARTNERS LP (10.60%). View Institutional Ownership Trends for Enzon Pharmaceuticals.

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.2665.

How big of a company is Enzon Pharmaceuticals?

Enzon Pharmaceuticals has a market capitalization of $11.54 million and generates $8.38 million in revenue each year. Enzon Pharmaceuticals employs 5 workers across the globe.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]

MarketBeat Community Rating for Enzon Pharmaceuticals (ENZN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.